SOUTH KOREA · OPENDART
EuBiologics Co., Ltd.
유바이오로직스 · 206650 · KOSDAQ · Healthcare · Drug Manufacturers—Specialty & Generic
Score
39.5
Insider timeline
One insider bought, 3 times, the latest (2 Jul). The share closed at 8,600.00 that day and at 8,080.00 most recently (−6.0%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
Blue line: this share's price, −39.2% over these six months
The closing price of each day, from 13,300.00 on 2026-04-21 to 8,080.00 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −31.9%
Taken from the 1525 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −39.2%, the typical one −31.9%, 7.4 points behind. It is not an index and not a comparison within one industry.
This company: insiders buying per month, last 12 months
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| Shin Young Hee | Executive | — | 1 | — | — | — |
| Heo Tae Young | CEO / chair | 3 | — | 77.7M KRW | 2026-06-30 | −6.6% |
Purchases against sales
Shares of the reported value of insider transactions in the 180-day window. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.
Insiders' buying price vs the latest close
Insiders paid 10,373.89 KRW a share on average (5 purchase lines, 3 buyers, 2025-12-29 – 2026-07-02). The close on 2026-10-16 was 22.1% below that price.
The latest purchase (2026-07-02) was at 8,590.00 KRW; the close was 5.9% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Heo Tae Young | CEO | Bought on the exchange | 2,000 | ₩8,590 | ₩17.2M | DART ↗ |
| 2026-07-01 | Heo Tae Young | CEO | Bought on the exchange | 1,000 | ₩8,770 | ₩8.8M | DART ↗ |
| 2026-06-30 | Heo Tae Young | CEO | Bought on the exchange | 6,000 | ₩8,620 | ₩51.7M | DART ↗ |
| 2026-04-24 | Shin Young Hee | Managing director | Sold on the exchange | 685 | ₩13,640 | ₩9.3M | DART ↗ |
| 2026-04-17 | Shin Young Hee | Managing director | Bought on the exchange | 685 | ₩14,000 | ₩9.6M | DART ↗ |
| 2025-12-29 | Baik Yeong Ok | CEO | Bought on the exchange | 10,000 | ₩11,695 | ₩117.0M | DART ↗ |
Other changes in holdings · 23
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-04-06 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 29,646 | DART ↗ |
| 2026-04-02 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 60,000 | DART ↗ |
| 2026-04-01 | Kim Rock Ki | Director | New appointment(+) | 3,366 | DART ↗ |
| 2026-03-30 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 20,000 | DART ↗ |
| 2026-03-25 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 115,572 | DART ↗ |
| 2026-03-24 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 25,000 | DART ↗ |
| 2026-03-23 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 15,000 | DART ↗ |
| 2026-03-20 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 10,500 | DART ↗ |
| 2026-03-18 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 19,428 | DART ↗ |
| 2026-03-16 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 10,000 | DART ↗ |
| 2026-03-13 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 10,000 | DART ↗ |
| 2026-03-12 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 14,000 | DART ↗ |
| 2026-03-11 | BioNote, Inc. | 10% shareholder | Acquisition in exchange(+) | 20,796 | DART ↗ |
| 2026-01-28 | Chang Jae Sun | Director | Stock options(+) | 5,000 | DART ↗ |
| 2026-01-28 | Shin Jeong Sup | Managing director | Stock options(+) | 10,000 | DART ↗ |
| 2026-01-28 | Jeon Dong Woon | Managing director | Stock options(+) | 10,000 | DART ↗ |
| 2025-11-27 | Tae Young jin | Director | Stock options(+) | 25,000 | DART ↗ |
| 2025-10-15 | Shin Jeong Sup | Managing director | Stock options(+) | 2,000 | DART ↗ |
| 2025-10-15 | Jeon Dong Woon | Managing director | Stock options(+) | 10,000 | DART ↗ |
| 2025-04-03 | Chang Jae Sun | Director | Stock options(+) | 15,000 | DART ↗ |
| 2025-04-03 | Choi Young Jin | Managing director | Stock options(+) | 5,000 | DART ↗ |
| 2025-04-03 | Shin Jeong Sup | Managing director | Stock options(+) | 10,000 | DART ↗ |
| 2024-03-26 | Heo Tae Young | CEO | New appointment(+) | 2,000 | DART ↗ |